Health Canada
- Status: approved
🇨🇦 Higher doses of vasopressor therapy for a MAP of 75 mmHg in Canada
Higher doses of vasopressor therapy for a MAP of 75 mmHg (Higher doses of vasopressor therapy for a MAP of 75 mmHg) regulatory status in Canada.
Marketing authorisation
Higher doses of vasopressor therapy for a MAP of 75 mmHg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Higher doses of vasopressor therapy for a MAP of 75 mmHg approved in Canada?
Yes. Health Canada has authorised it.
Who is the marketing authorisation holder for Higher doses of vasopressor therapy for a MAP of 75 mmHg in Canada?
Centre de recherche du Centre hospitalier universitaire de Sherbrooke is the originator. The local marketing authorisation holder may differ — check the official source linked above.